In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Dans, Antonio L ^a   Teo, Koon ^b   Gao, Peggy ^b   Chen, Jyh Hong ^c   Jae Hyung, Kim ^d   Yusoff, Khalid ^e   Chaithiraphan, Suphachai ^f   Zhu, Jun ^g   Lisheng, Liu ^g   Yusuf, Salim ^b  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b MCMASTER UNIVERSITY   (Canada)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d The Catholic University of Korea   (South Korea)

^e UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^f Chaophya Hospital   (Thailand)

^g FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HEART PROTECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; SYNCOPE; ASIA; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ETHNIC GROUP; ETHNOLOGY; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIA; BENZIMIDAZOLES; BENZOATES; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ETHNIC GROUPS; HUMANS; PATIENT COMPLIANCE; PLACEBOS; RAMIPRIL; RISK; TREATMENT OUTCOME;

EID: 78650969240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013694     Document Type: Article

References (17)

1. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145-153.
2. Dagenais G, Poque J, Fox K, Simoons M, Yusuf S (2006) Angiotensinconverting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368: 581-588.
3. The ONTARGET/TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 148: 52-61.
4. The ONTARGET Study Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
5. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 372: 1174-1183.
6. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, et al. (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225-1237.
7. Dans AL, Dans LF, Guyatt GH, Richardson S, for the Evidence-Based Medicine Working Group (1998) How to Decide on the Applicability of Clinical Trials Results to Your Patient. JAMA 279: 545-549.
8. MIDAS Retail Pharmacy and hospital database for Japan, Southeast Asia, Greater China and South Asia: 2005, 2006 and 2007 data on Ramipril and Telmisartan. Accessed 2009 Jun 25.
9. Corbie-Smith G, St. George DMM, Moody-Ayersc S, Ransohoffd DF (2003) Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. Journal of Clinical Epidemiology 56: 416-420.
10. McDowell SE, Coleman JJ, Ferner RE (2006) Systematic review and metaanalysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332: 1177-81.
11. Tatami S, Yamamura N, Sarashina A, Yong CL, Igarashi T, et al. (2004) Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet 19: 15-23.
12. Anderson PJ, Critchley JA, Tomlinson B (1996) A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Eur J Clin Pharmacol 50: 57-62.
13. Ding PY, Hu OY, Pool PE, Liao W (2000) Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens 14: 163-170.
14. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, et al. (2006) Angiotensinconverting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Kidney Int 69: 1438-1443.
15. Lee YJ, Tsai JC (2001) Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 50: 1346-1350.
16. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, et al. (2004) Development and Validation of a Clinical Prediction Rule for Angiotensinconverting Enzyme Inhibitor-induced Cough. J Gen Intern Med 19: 684-691.
17. Agency-wide Race and Ethnicity Working Group from the Office of the Commissioner, the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, and the Center for Devices and Radiological Health of the Food and Drug Administration (2005) Guidance for Industry Collection of Race and Ethnicity Data in Clinical Trials. Clinical Medical, Available: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126340.htm. Accessed 2010 Sep 27.